EUCTR2021-003191-14-FR进行中（未招募）1 期
Cohort assessing the immunogenicity and the safety of the COVID-19 Vaccine Janssen in healthy volunteers based on 3 age groups: 65 years or older - 55 to 65 years - 18 to 45 years - Covicompare-Janssen - Covicompare-J
CHU SAINT-ETIENNE0 个研究点目标入组 180 人开始时间: 2021年6月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-At least 18 years old: >65 years old or 55 to 65 years old, or 18 to 45 years old, depending on the group of inclusion.
- •-Healthy adults, or stable medical condition for adults with pre-existing medical conditions. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment, nor expected to require any significant change in therapy or hospitalization for worsening disease in foreseeable future.
- •-Understands and agrees to comply with the study procedures (visits, phone calls) and provides written free informed consent.
- •-Able to comply with study procedures based on Investigator judgement.
- •-Affiliated to a social security system, (except state medical aid)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •-Subject is ill or febrile (body temperature = 38.0°C) within 72 prior hours or and/or symptoms suggestive of COVID-19 within the past 14 days at enrolment visit
- •-History of documented COVID-19 (PCR+, antigenic test+ or chest TDM+ or serology SARS-CoV- 2+) prior to the vaccine administration
- •-Subjects with positive serology to SARS-CoV-2 at the enrolment visit.
- •-Subjects who already received another anti-SARS-CoV-2-vaccine
- •-Subjects who received BCG given within the last year.
- •-An immediate family member or household member of study staff.
- •-Use of immunosuppressive drugs like e.g. corticosteroids at a dosage > 10mg/day (excluding topical preparations and inhalers) within 3 months prior to enrolment or 6 months for chemotherapies
- •-Received immunoglobulin or other blood product within 3 months prior to enrolment or planned receipt of immunoglobulin or a blood product through study completion.
- •-Received any vaccination within 4 weeks prior to first injection or plan to receive a licensed vaccine 4 weeks after the last injection.
- •-History of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as rash, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of allergic reaction likely to be exacerbated by any component of the anti-SARS-CoV-2- vaccine.
- •-History of severe allergic event
- •-Participation in another investigational clinical study (Jardé 1 or Jardé 2) within 4 weeks before the enrolment visits or planned before the study completion.
- •-Known HIV, active HCV or HBV infection
- •-Any pathological condition, such as cancer, which may be susceptible of reducing immunity response
- •-History of heparin-induced thrombocytopenia (HIT)
- •-Any bleeding disorder considered as contraindication to intramuscular injection or phlebotomy
- •-The use of investigational Ig, investigational monoclonal antibodies or convalescent serum are not allowed during the study
- •-Any condition which in the opinion of the investigator may interfere with the aim of the study
- •-Pregnant or breastfeeding or positive pregnancy urine test at enrolment visit.
- •-Woman in childbearing without efficacious contraception (in the opinion of the investigator) for 31 days after treatment
- •-People under legal protection measure (tutorship, curatorship or safeguard measures)
研究者
相似试验
已完成
不适用
Prospective cohort study on immunogenicity, safety and efficacy of seasonal influenza vaccination to healthy adults who received non-adjuvanted or AS03A-adjuvanted pandemic influenza H1N1 vaccination one year agoJPRN-UMIN000004631ational Hospital Organization, Tokyo National Hospital100
已完成
3 期
Safety and immunogenicity of rabies vaccines in animal bite cases administered using new one week intradermal regimeCTRI/2012/12/003230Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS80
Unknown
3 期
A clinical trial to study immunogenicity and safety of Purified Chick Embryo Cell Culture Rabies Vaccine administered intradermallyCTRI/2010/091/000509Cadila Healthcare Ltd36
尚未招募
4 期
A Clinical study to evaluate the immune response and safety of double dose of live attenuated Chicken Pox vaccine among Indian children : 12 month follow up studyCTRI/2016/11/007452Wockhardt Ltd305
已完成
4 期
Protection and Safety of rabies vaccine when administered intradermallyCTRI/2012/06/002720I70